StemCell Therapy

%PDF-1.3 % 236 0 obj << /Linearized 1 /O 239 /H [ 1988 410 ] /L 152378 /E 110030 /N 3 /T 147539 >> endobj xref 236 55 0000000016 00000 n 0000001451 00000 n 0000001806 00000 n 0000002398 00000 n 0000002869 00000 n 0000002908 00000 n 0000003067 00000 n 0000003225 00000 n 0000003872 00000 n 0000004096 00000 n 0000004311 00000 n 0000004736 00000 n 0000004958 00000 n 0000005340 00000 n 0000005558 00000 n 0000005792 00000 n 0000006252 00000 n 0000006282 00000 n 0000006323 00000 n 0000006551 00000 n 0000006573 00000 n 0000007404 00000 n 0000007426 00000 n 0000007648 00000 n 0000007986 00000 n 0000008857 00000 n 0000008879 00000 n 0000009723 00000 n 0000009745 00000 n 0000010624 00000 n 0000010646 00000 n 0000011550 00000 n 0000011572 00000 n 0000011728 00000 n 0000012020 00000 n 0000012831 00000 n 0000012853 00000 n 0000013721 00000 n 0000013743 00000 n 0000031758 00000 n 0000040546 00000 n 0000065801 00000 n 0000077006 00000 n 0000086677 00000 n 0000086756 00000 n 0000086963 00000 n 0000087037 00000 n 0000087106 00000 n 0000089784 00000 n 0000101530 00000 n 0000108385 00000 n 0000108602 00000 n 0000108809 00000 n 0000001988 00000 n 0000002376 00000 n trailer << /Size 291 /Info 233 0 R /Root 237 0 R /Prev 147528 /ID[<917cf852d21eec3aeb020f84b0692ea9>] >> startxref 0 %%EOF 237 0 obj << /Type /Catalog /Pages 235 0 R /Metadata 234 0 R /Outlines 16 0 R /OpenAction [ 239 0 R /XYZ null null null ] /PageMode /UseNone /PageLabels 232 0 R /StructTreeRoot 238 0 R /PieceInfo << /MarkedPDF << /LastModified (D:20060422135029)>> >> /LastModified (D:20060422135029) /MarkInfo << /Marked true /LetterspaceFlags 0 >> >> endobj 238 0 obj << /Type /StructTreeRoot /ClassMap 29 0 R /RoleMap 31 0 R /K [ 168 0 R 169 0 R 170 0 R 171 0 R 172 0 R 173 0 R ] /ParentTree 187 0 R /ParentTreeNextKey 5 >> endobj 289 0 obj << /S 151 /O 294 /L 310 /C 326 /Filter /FlateDecode /Length 290 0 R >> stream Hb```f``? 0Abl,{N400=h8Z|<< /Type /Page /Parent 235 0 R /Resources << /ColorSpace << /CS2 253 0 R /CS3 252 0 R >> /ExtGState << /GS2 279 0 R /GS3 280 0 R >> /Font << /TT6 251 0 R /TT7 250 0 R /TT8 243 0 R /TT9 248 0 R /TT10 246 0 R /TT11 259 0 R /C2_1 268 0 R >> /ProcSet [ /PDF /Text ] >> /Contents [ 256 0 R 260 0 R 262 0 R 264 0 R 266 0 R 270 0 R 272 0 R 288 0 R ] /MediaBox [ 0 0 612 792 ] /CropBox [ 0 0 612 792 ] /Rotate 0 /StructParents 0 /Annots 240 0 R >> endobj 240 0 obj [ 241 0 R 242 0 R ] endobj 241 0 obj << /Type /Annot /Subtype /Link /Rect [ 126.66039 75.46454 250.55365 89.11163 ] /Border [ 0 0 0 ] /H /I /A 281 0 R /StructParent 1 >> endobj 242 0 obj << /Type /Annot /Subtype /Link /Rect [ 262.74039 75.46451 361.06534 89.1116 ] /Border [ 0 0 0 ] /H /I /A 282 0 R /StructParent 2 >> endobj 243 0 obj << /Type /Font /Subtype /TrueType /FirstChar 32 /LastChar 181 /Widths [ 278 0 0 0 0 889 667 0 333 333 389 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 0 0 0 0 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 0 722 667 611 722 667 944 667 667 611 278 0 278 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 584 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737 0 0 0 0 0 0 576 ] /Encoding /WinAnsiEncoding /BaseFont /PPAPMP+Arial /FontDescriptor 244 0 R >> endobj 244 0 obj << /Type /FontDescriptor /Ascent 905 /CapHeight 718 /Descent -211 /Flags 32 /FontBBox [ -665 -325 2028 1037 ] /FontName /PPAPMP+Arial /ItalicAngle 0 /StemV 94 /XHeight 515 /FontFile2 276 0 R >> endobj 245 0 obj << /Type /FontDescriptor /Ascent 891 /CapHeight 0 /Descent -216 /Flags 34 /FontBBox [ -568 -307 2028 1007 ] /FontName /PPAPAO+TimesNewRoman /ItalicAngle 0 /StemV 0 /FontFile2 275 0 R >> endobj 246 0 obj << /Type /Font /Subtype /TrueType /FirstChar 32 /LastChar 122 /Widths [ 278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 667 0 0 0 0 0 0 0 833 0 0 0 0 722 0 611 0 0 0 0 0 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 0 0 222 833 556 556 556 0 333 500 278 556 500 0 0 0 500 ] /Encoding /WinAnsiEncoding /BaseFont /PPBACJ+Arial,Italic /FontDescriptor 249 0 R >> endobj 247 0 obj << /Type /FontDescriptor /Ascent 891 /CapHeight 0 /Descent -216 /Flags 34 /FontBBox [ -558 -307 2034 1026 ] /FontName /PPBAAD+TimesNewRoman,Bold /ItalicAngle 0 /StemV 133 /FontFile2 277 0 R >> endobj 248 0 obj << /Type /Font /Subtype /TrueType /FirstChar 32 /LastChar 116 /Widths [ 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 722 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 556 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 444 389 333 ] /Encoding /WinAnsiEncoding /BaseFont /PPBAAD+TimesNewRoman,Bold /FontDescriptor 247 0 R >> endobj 249 0 obj << /Type /FontDescriptor /Ascent 905 /CapHeight 718 /Descent -211 /Flags 96 /FontBBox [ -517 -325 1082 1025 ] /FontName /PPBACJ+Arial,Italic /ItalicAngle -15 /StemV 0 /FontFile2 284 0 R >> endobj 250 0 obj << /Type /Font /Subtype /TrueType /FirstChar 32 /LastChar 51 /Widths [ 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500 500 ] /Encoding /WinAnsiEncoding /BaseFont /PPAPAO+TimesNewRoman /FontDescriptor 245 0 R >> endobj 251 0 obj << /Type /Font /Subtype /TrueType /FirstChar 32 /LastChar 121 /Widths [ 278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 0 556 556 556 556 556 556 556 0 556 0 333 333 0 0 0 0 0 722 0 0 0 0 0 0 722 278 0 722 611 833 0 0 667 0 722 667 0 0 0 0 0 0 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 0 278 889 611 611 611 0 389 556 333 611 556 0 556 556 ] /Encoding /WinAnsiEncoding /BaseFont /PPAPHE+Arial,Bold /FontDescriptor 254 0 R >> endobj 252 0 obj /DeviceGray endobj 253 0 obj [ /ICCBased 283 0 R ] endobj 254 0 obj << /Type /FontDescriptor /Ascent 905 /CapHeight 0 /Descent -211 /Flags 32 /FontBBox [ -628 -376 2034 1048 ] /FontName /PPAPHE+Arial,Bold /ItalicAngle 0 /StemV 144 /XHeight 515 /FontFile2 274 0 R >> endobj 255 0 obj 751 endobj 256 0 obj << /Filter /FlateDecode /Length 255 0 R >> stream HU]O0}Tq! MHf{7IfJR~SMn-Oob~H%]a5$AShV}[`%<9*cB^A0GH2e.u_jahVp?3L_)S,w5-l^(Wr5N.f]xlrW8o*(?s{rr '!9e*i-.6P6eE5}|'W7c?boY.UOm$%sUxd}D)E 8W*5,-em1z%Lc9bs 5N0p:.24 2T2;7jIYL C1M F|D CcrRCC$Y*Ar,:eHQyJ0RIiST%,]yqyiX M# ;w{m4vY][_7> endobj 259 0 obj << /Type /Font /Subtype /TrueType /FirstChar 58 /LastChar 121 /Widths [ 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 611 556 0 0 0 0 0 0 0 0 0 611 0 0 389 556 0 0 0 778 0 556 ] /Encoding /WinAnsiEncoding /BaseFont /PPBAKC+Arial,BoldItalic /FontDescriptor 258 0 R >> endobj 260 0 obj << /Filter /FlateDecode /Length 257 0 R >> stream HUn0+R j 8CUo6c3Tc_d4Lg38/&_1I.Y04PZ _y(KpP>NrxAR?n.]"(dN jNJ&<]6SpUNtNT!FH6xN+Md^h}*LcFsE *~lS-r6s>8a2u=xcjBN"=0I@H:fTv^vN}4mm/ NLJ*4f_55v=B.$U~Q9[jUyokhz5u?IQ1 G&YvU|$<,D RiYYN "KWal'18*J"cE$R OX9OZ]sL96% fpD&dI~0!r27oJ+:hr7&?q///g_nofr,xbE21Y]xyh`IHMKfm}r Eh1I:) 0IQ>|Zkg}@o, py+ED"K!HoJ endstream endobj 261 0 obj 764 endobj 262 0 obj << /Filter /FlateDecode /Length 261 0 R >> stream HUn0}WUwY@Q`-{SVu_?E^:!QJ|wk&/I_Bq}XJE C%hA8P+1m 5TM>>nM}wz(c?,-l8q9aHfwMh`8dweT7m.m^(B55L}V:"J1z=^-fW.f'?6o7$_^ftd7Dc!5'cb6_c,PQ/oISrQ$DlC~J{mr1S[., PU%dpm:;=Q= 'MW"~52e pL_!]*T?[6=65f|SBIw_|De5tH 9IcY>}!-@>gKs]JavYc0UKqGn~7TJh)(IZjpyC|>dnjjzpmsHb)^63QBlrh: `x4U1!~{&12n58qHOEjs}+ endstream endobj 263 0 obj 799 endobj 264 0 obj << /Filter /FlateDecode /Length 263 0 R >> stream H|Tn0+R , FmhToPV{x8Ynf{i~wu{ r1/90X,g%% YJX?of'pxE;aQT(z/}3Y0y84+J0t4uKm7=-UAs MeNw[$dzE(=$$y8L(:r~'x)'D&x7f[1K!`chZO#,v3igvjcCzmsV`2'_ka~p3nq{?iZ9(0;=f^TZb9)8Kw.&o %c|@ItB+@1nVP Rigb (:0ar+3y)YJC59/hF)#2,Vi`/)%f .S7g}k^wl.CS]xsA<< /Filter /FlateDecode /Length 265 0 R >> stream H|Ur:+z3UIUF$'-Y`F3B,M:2eM6GBcB+`RNsqM @{7>r 5;;xx&L)MDlKh1/GSx7[8NQASDTr ]Fp>Ven5~YG3<]N//X!Q##}}NGcz%6%o[3M /GSTLMy4/f/;15[snZW/GPM EJ7m]%]u yZ3LRK/I-.6{_b)C wc1T22WBvtqT9%$J5@7GT)-9ZB;XA2X LCkzT%hPB5wu%NIue%`?T;f]RTOG-S\^I'B:V<)As XZ{YUfm gWI2^;S!4BZmFtv?V7L6c!h]t:>N=:nu /P%s{I8x~J2bA%0&+~<} ZVXF`:L}L}~8).?nU.gY^wy d endstream endobj 267 0 obj 731 endobj 268 0 obj << /Type /Font /Subtype /Type0 /BaseFont /PPBBFM+SymbolMT /Encoding /Identity-H /DescendantFonts [ 286 0 R ] /ToUnicode 269 0 R >> endobj 269 0 obj << /Filter /FlateDecode /Length 217 >> stream HTPn0[t6nwE1%: :n 8m5 R;U ?N9k]-g^nzj$[pZq`{Wj endstream endobj 270 0 obj << /Filter /FlateDecode /Length 267 0 R >> stream HUMO0WX$j8 q *UD9jIh8`yL,_t}}^CLUtEWY&E.",GpLQ82Do8IR1b*Jt]d gWgjQGoj*jL r`n>A[] ) jsm|U>Ntc}0$vh(c"z4607h(g$dXpP{,M0JL_Jc%A J`I!]V8 q0Ix9C3xVV4k& fvi{}RN *C%s:k jX{`^1XIy|Xwa,oM ]U(s=FXhC%X`1gEC(`"1,*!F;bt6h%Non 10-+8x~k[[;H+$gdxw/D<< /Filter /FlateDecode /Length 271 0 R >> stream HU]o0}/R)ql>V[M+&HPUl"s&SJD1Mo[Fh1HO( H3]_^@gp|H)l5a@V9|I=l`S+[`SAXXMVa{fe ~ Vq41]`? endstream endobj 273 0 obj 770 endobj 274 0 obj << /Filter /FlateDecode /Length 17923 /Length1 32020 >> stream H|UtW97oA7 MZA$7!"VDR"&3N)5J=:z.YYJJ(r2Ykz:}Hd8TA`^fNuw>3 ]'5iRsS!/mse'M8}H%|Y8w-Z1x lz?wNu*A5isO3*7QtveDy:DX0y?]jy~e}o[ c+A(nS8% X_7:+:db8 sy :mTen1n3YqI^@gNb<6k AK1wujvoXd1RtAjEylbLq)X7)~xn e5eb47s#3R4BU C|zficmGhm|'=z&bSDYae(tee[):V[duYwu/uov7f |c,K9O4&;ZF5e#'k.^`?Ubk?sqJR1|^.?`z5RQ&G&Qj~%Rd)|gVnv wpoLXzF!g78 dw?4qTLUTC}mV'ZWE#SqBp8$Mby(r7(dKbzq8I~3k~#Iw$QRXrZM4eo^NnY>dpSfw`R B~7$pgITHE; h$zsHIIg#.gTCjsfo Ow4vw^<,y39!Pg$yv))7eUu}Jw3Iq`P^X I-aMGNyZE(:W+l]m3jh4l~/>}P?ejaEVGdWZ7DP@b)K={8:H N8LIaXSqOOO 3W{}0pK23 xB~D$2 3RrbDW$BAOro7ntA)s[y K}9 yEbVH .Ud;$'(")A5 QVLp:!U)dk s=`faaP0^5Y+*b r}2M,VT82_iHn.$2ml/zs~[u;ImA! ZAqi+-A^5V~*F5ngQ< d,YP8@p;*KvSM6Dw!}AM K[OCxVbF#H#/#=o1&C8m`aG$:7,dx#`#`GT;Qn?7yc9abL} :[Qcs8w9 e1?a< q>hT2~~9^[JkPhKX`Y*(AFAa~;nz`/A1(# 6Y B5=/cD}?-J,mB{<5eka*1~-Ck,G-kGP:X& :|$4G]Iwa5w.pO=q7,qjONS4t[[|w)G>s>FoqwS' m.%d^=mv.23f;=)rs^tQ-VY(=Z"bUQ%-v;mTh>JyJWR>j-H([DcU'!]xg-Uq_Sv~Tz y4V6z6Qz)5D/4,=wf=.b.4&@A7)#Lc?Gx_qdyzI)""kYiX'r"C}{}Rr6oBK8%ge+{{zm?s_^>'{#3|. %|Vp2G`V6w@7&cr,9V%Y^?^;3@Pka/|`v #>gs3f0Z~;kqcoN qYX7U|'oq,3^;J+$oCCCEz6upsLKN8nAPT5H&KMmHiJ[ik|npU6uX4*a)NKDwiyl~0bk"U4O@"+%w[Ub@3F (zmB2KvEqDtQ)y}}Pm{ g=i@~*BK%(F>civ ! ]]eV.>9NEae}(BBoDobnKW`(BONg wHtq b L1P}4CMjoc$`{?(.O$ 0qPs3,,F(L7_a-|(6~/f;n|kBKF0{5,?.I*I4nitME@ge5!~XK4GV Xc'@Ye_ }X?=.Gtu6Wr.Q7 m+CL(2F]E4!FBs C<1Q#ni=$rAGTHh** _MA4#S47TG#*BNu(hF?WciQ72t"$r_3 85)[NyEq{?I85)pf7p{wvrho#=lXK6}&v7q;|'IY-$Y D%* #I|% I>5X -D"zS}oEC}op&J^GY=i7pnG6tD7Sq7D"6l`igmzjiLESKs UN)|,zlg? FYk6[Fo$IKuR+<,"W,u}}YU7q-rhUvbAox)Yok8{#:i'u'JqY*%TT%+UXY<{p72Er,= @`Pp"7uILJGPWD1X ,{{6=]{3=_O@- ]Z'eb>D |/{gQhrQ$RP@ ^G(K^'X/_JD2NN4LJ'vHHRu$iE>5ImnSUIrVz59*.N44pB EyqQ4 3Pkz-4#wpsq|5Fs:dEANHR%HU: PBD T>w'IzFx_pV.OKB/Hd,ULfT'*$J%"(+3t(d%Xh1-k+{uw[3f^r4Pv=^o?g7V/m[vm95CO3)(!ZNx_8] #48D'gitT7).o,E=+(/CLU+e1,v;8cX=r5lS^EUFxQ^[bVbtoVSQ9 J YGcyZb4_j,7hw5*`8tM0Z!p7#,%jtpaJOYf)!`"ADQp!sf< Lx|/@8!@7jM%kvVU{:N;l6O;<8!QEE>O)?e#jUnwht% mZqIE1Hn&2.JMVnrrwD5p371XySMUqa2b 9T:qa8b)6d7q+ >E7lH=mzo[sqKJJ[wkGx_osUm@AUat v(_o=j+pJ x[~q7c`-^m |RrJ(TRCHgt-G5(R B];x1dn(j@gBt%+8Ju gX3jyr,jKYL dz0(8SN7g|oI)@UdS63hn-`<:c+gxme4w7ws;Qi!`2MZfi1x% etPo+h?%cBJ?)`^%dj,eEl'}<&'mb<'.+]Wur}.!y2^61VD,md5'il&ge'N ]pMK, @'X_E2CS'u.F-t#`.Ywd&+N6NhNQEzHt`"`Pq+I 7JA1._S#f`1xUt~l!`)aQ8X'g'Azurl8g|nj77H~_vARV2l"5-; y7k8 jij .Qts~dMEvh%%!((GR^V=O;`g~6i{y_^]=sWvK%,_iegY%a[ $"Q H1K t[p)M`m FHXW`)q~r($g,=> K(DoH u1~>_w1fNS5)<2/XWs |xqorm~uiOv{7x;XXU8/+h_&e0B8y@J5aK; y  ?P2`'bm6-=ASTG^&y3W%oB/q#~Lc"WM(p~ k RJ)&5.c?V{d_QHU89hE(9%Q4sVvok$##{e)Gsk]T27lWO#rT 248C/P }(~qUh5-oY "%m$)"3>plK#a7 2Qs'7u aCtdP,naZ|-jkI vG$ki;/d#COQyf.d@*yo{xxjF0.RFhZ}[NxQ}_o9oyo)i^iuL*}m}mvkG#!i- OIs1*x0uIx a~rjF8XU=b G VHa`4&?X "j;!Cq;bNg8{ob X__`UIq^@Q-fUon!owmEa$#m65} v-o:snfYSQ1IST:C{BIh{MF04]5Mg|};qw'$2B}qJ,^W )Sti(Td 4@VfTvCS' uc B"IY;hJF1-a1Xq!]#(uDS& ibHQ8Rpt!rMe1OaMV=a]/ZhHiX_+5PYSTyzvg"}BG5U@3U(ed][/wI4^RQ^U'a6^fh]2!2dciYh~NE6&nca>,fS^r8F@@GN_,f8ycTMn7A+1Wf6Jd -+3= 45 R%6K@ RTmA%@Swlzrukou'OjG'~xlzP,q)Z*} e:K-v%tc0WDXeYUDrhC8/"{;KUcRAc){A[ OL7[SPCCr!0Kcw}uExNh?5yWLo0$9$ 9BpdM=;Aw.M2,AS$T*B6ahh".IP>]H)HaQ^ n/w "sD&|RD43G/W4n"bf'zb'K|k7A0Z4BM-`O|LXD8[{a3E"?X=< v-ta"!)_dy+4YbEI U tS7$ /P B-DpBTU5C)',o ^%pJ5thC# D4JvFO7b,:T:f(L7ST za^Mxj|<691;bd0L&N^6XZ,0 Zbv|.kf*fh j Y1kvVKSITcn4P[~p;waYKw] 8X*JWD{{2IcqQZ'7z{p/k(=3-WN)()a`|s3@kz)d9jr%`qCcQp}wP"/^;Juws0wS'{I".L5B+Q&W +]qA>LD}bvCES`{V-RD/fQ^} "i1in27sf;'>OF7;hbowRVxO8;IXK Nv{rH~;P?4>)5 vtMg rr lwOS/4z|y]yE?"Z8{#.)dBr J 3'(>mIXx;(0thJBMv";FF)i0^1Q3cp#iP#>xV=wzs`/l{0btW1{]T`d: 0EQ'8vhiMy 'e7oZU_~3weis7V!r?q]y{4A.1jogB+ySLe"|^H>fqL3I|{Nm8w2_5p*%-SxN L!N$FDFdF3b:Nk:48/Vj%4j?xHJA3 @v TqDDYIXJnTnSPyuKZ$HG,HOB/!0`,flk?s>d7Md5]=fWARF& :?&9TolV4DX7(7%#mi^d)LbLlvCFIj%i= IQ^M?FuQw}Az:MgS ;:?zvbQS,}SN }d|0>gOPULEs5:f-{Q]X+D Xh-p-^%H7&bJ~1,G?fStsmOZr; =9Mp>VI;;Y w-}!$` 'OoWU$ R;fCk[8nrcch#y,W#3 HsdT >mP *vb?()l/PB %PB %PB %PB %Pl3",9".|C_T)=]?w#0|m#pg04y4A+*Xa3H>oA$qGwtC/&`>nOw;d]x>YDY*Rf)8a(~Q(((3_3gZz1*DtAITSLw8N| @V@ !AC{8Lmpn~{|8BxDfyK!;o?K) endstream endobj 275 0 obj << /Filter /FlateDecode /Length 8697 /Length1 19988 >> stream HUtW9o$I1r+g(F$AE(-K>|.@#{9 @]N7I=]|wp,tVm3Io*e_Et.D6 zM8nUTR:vphy2w 1ed+0knw'<'o@4VCIT~Wz)G`4lED@!abc.ULMC,2qE;]gbC`b;JA"/qT#Vn!Zc6G#W&VGDb3g%VfB1Wm06Wm"2jNB^xW(%IY zI'V$ D+a$&a:op=[7fk>C2NTeCq12@K,R%rH5Y~}D_:I%1EYw+J$0s-3{AZf1>4|*]C/S[2O^ [w:W/+kkd6701pdwYZ#Sn@~>b fa.ce6aqoH$9cv|YFer]~"bUgKtU+ uN-h=[!6 g3tm>@YfIH@;2]HGGq#Qbn>A0b$/El#Y*Q{9XG:]g,e[VkUh['S;EFccccv;g98MP4O{~$:T5C]>{cj.)@jz`tDOsv.*C]O$5AV5HVoI:yH7U{: uM5Uj }2Xh`{EV6vj~V+&%ddR3F UWHwJ^ct(1*TC5LsDhiD55C59-5}5m_gu<=^SGqt^"Wk11,BGP-m6*Z8QPg!.jZ5oX*S8Z]i0Fve;[o7xvQ's@R8" osOl+gxGxryf* 1lN7;5:RcAG2v.Q%d^f9P#-z%xej*MADH0L1w6gZ)))z{r]:wRmhIF W:ANmi%hs~+MF# 5e}}#sNdw.54E/=X>W0yt&_ }zT0-Ciu?-+8LPTp4c't([YYc*czohbHeXN%V^S[ FHWQ1QZ To{jfx.-xA`/QoG8GIqkXrOfMhx}0b0FEqYFTGo,>8&b"f$~nc+r~#'0>|PFV+]rIuoR]0;(OS&g@e@X<4 |p vPk:E>W+QT[CfTrt%{z+Z1n @?<*F=`! ucCFak"/Fy.1_V(I=`8A8` xx`? vGcfn1g }{ 9&uW[ s+M0YC:@UY6D89&)cRt(#_> B.=M$2hfR=T}-CbxUo,NkRErZ6r2`X2uiGoA%<W~G0zC.oYB>_fi4_#.%B9'XB%1sZ9zCN(ssIJw1UmAUG-s2?sx:ii?`/ir$dnvcrU;_=h/50B={9s~jvgW#/S4#y;:M<,T;nQ2mcX7{M.>jErAy9v (OS)c{Aw`/yncfZ7yTpAUX?(o5Z]GS4M(KoE*AG~G2WKi~Y Z*s$w Meh:t *o`(iY}{MOx-Mcl7ln,=9>1(wa2B~? /& mwUZCzH=nu;PG_?hC>89|!|3(}/oP~3[q1~[07ix@mc@*?nuXkJGl6>G(rQA>= mPE`O?z)FX0UP.>Cm/Kut hx-a(22k Uispo6zjI3ufhos7(gi^5xLp9*ll[Q;Tk:?!9;=ywGM^|2y$t'ok?F-m"{1=P'|9f;#U?o !cPR#m4V_;Kvh{Ml|)~'ao]r1/ wSh3|=]p.Ed1:`fB1jZmv]5KIt3tQv9g?d<9={}] @Q7 a=zlx.7=n~P #JNa9n dM@!Spy{w9]K[D_7IN"sADa(O`#m'F(j A ld+{g]c_dBK}}iJ_FdZO=P'(Z:;&`vJ tOJV.K}XN,}'V+IlputbVt 1XR^aa-p'zYcfulgb_`Oa TbInn9OlDhfZ"Uz[XRD=d-B(`c-Va =F8.eFi%$rVxCUE,}Ep$hzmmzok|5~[XpD/Km>KmjV.a, #80sm@2":Lj8QiJh rkj"^!C2:v<)5>iQ'n va q vr @v0+)C,`hrh4YG,#*f*U 4?qLrhg#ZMD+h 'P*UcFvQa~J7_{$_[dKv %WI^nskN%IL?8DZ"T:c"Vh3::/|V YHN+maZd: !n?SF "UR+Ji%=GVUO[)UOXG ?!OLpZ#NRSLS+tHuR+qKKtbsOj&uk@GgpmCe$/_&68. =G&bzva]zuxSVz {pxBs;a@iG)a&dX6-"m3%VB>2ZCLu_j:'hC* 8SY~Z?E0M4]RW4@Wk-Omj5Qs6n&=:JZ*QhjSkcD@lwLDY+>&/87wPHf[Q;j& mwjd))M&i MT+i"RVDjI?dTh:Jqi7ofvv73t5Ck}r}/?)[6ol-Bp.^]Z5:MhvF>4/t 0Lg&V]H -?f%Y1N2 NM;zooap#(b/B_ =b/D]9f]ic#lHC}SrolZ^Fy%j;N 7?"F!p}UJ)jTRU-p6U{ 4+0 (QdLj$DC_V)IXz *i]UsMUdu !V}U]/&a?KtyPdd]:n2S.Qop:NjD,yj8'S'TY&TSH}[4Wq3q5*uH;ux}};:|2""/?;?L:+MR}UOxKvN[G_j=6[-#qDn9%[srrO5o2WgsUUdpyN,~=O~+O{_hZ~Yh1Nh*WX9}h4?Y~p3w0`0`|0*ia$RG&}:}PCd :zIA7V"[RZA :LA7ZOO'9r@C{F?qmx0G$CFvAcic E;e)1$[0 bmf%O?=v[.sK, endstream endobj 276 0 obj << /Filter /FlateDecode /Length 25163 /Length1 40172 >> stream HT XT FFDbkAS%VMpAOiPbjc5V[AIMS$,D31Z;{ss@$C"w)>wP_rdAn#@ix3o|{nV%Bls3~_ '6*w*{[(>lx"R1}.tM=Y~XIi0/^:j3tM3,2i2WYRXn)*q?`;Wv8tWHbA9~K 8B_`!z1bX(6ztF|+-cd/p/+8VdSZA[lO;o'@`u6p d^FW>C;9{/L>Z7!;;%R*e12i&U"FJBc'ts=B9?.QbXTbhUFL4Y,VwyE~/b2pKIPhe2_USSpKeOTk5:zQma%BA8qZ~"-SEKIVYav%~W"d6 )fhSqm"8)|*/U)Cmb.8n8d=JZVZzDJ )rsh{"1p$ZEQBI]M[-yGw}/vu< XU4W`VR $=xO*8Tiv90Rf$;'bOL/PO)vM%jSb:MHyPcV| hs9(Kj, j<_F;b5~d"U'ZC~/8y9>"fO G9p*Vgi#R>|! >L ^#nC;EwEwZTE BKhFP1ck}(AC5XsiLIpONfdZ3Ms3.C7H6Aed.(<1"<]O/ONBcx1bR)FHN.#Nf`xs2;IQFGgH0%hejFkL:_Vy F_o;k.2-k47ywo~>`[gr Gn9$XuWPQz70~vKOtcDw=>.M{p'91`:el3BH=Y f? ahgO`?VFH! 5>Z7}{Wb { HL5sL &'-h!;^^w}WuUu %!@!$$ W D!uK%<`&<%@iAbR*6RCC;S(9~k}.7/^k^{YtcJz5B 5efl 700q63JDot:U&*1tUYkBIHAGTJM(/rZ+Knh1`0.%Hw:3<+J8iI 6 5LRRqtEDrSs#e-vxEjrBj~N?0 hnU)|ZI=}k!Jkr.}-{Z!N_) ETHO0GQm<|}!W`*PQre=}1GF zm0pz65XShCwFM6j~%t%P^~Wo0`A?Rib&R11 m3ZUjmv=Twx.7rC`4E"um[W6 x`_+6/*>BDsYv'^kxnA~w)#88?7"9J!u+o<.m+>b5 Bi7K]=jf:|!XE^1l^#J{k?aw(Q1=}"nN4|US7b:R;uf1[% k[i?F}v/~6vA:"_V1mx:'H?I_xp|/0=IT3TSU3q "= W%rS%r&g:`&rcw1^k0'PD9V9UCWm"Ob]mT&z;2FR6;R1*3{mBCw H]Z@OJ}67w!n=%#4Xt;OhWhh*E"25dEzkk($%}S,qx{~'#CM!gk;G.f.Ac^.wtm}r<.q4jjj?,c}Wk@9@Zp@4Wq w `@/[Ppv@o0YI.`3i"3t7n]t_wqf!R@K4.2MK]jWk#Vi^WkO~X<1?O[K{VY!'m"cZ;G!O#&_Yz3=O@:9e?x e3b>y6.]s1 wd;'R O3"-n@_C D?BQHZ/T_DQ97kPx?k= >XqE%(? -u2,+a0io;fw?{`=%nefzhg}TxR?cA?X,~< -+oV@-jm7 I'1 !$Z[RXT1]Di+uA#]N@J-i71WcGQU06kF=v0egR"B>&Uj&(B@95,dmw65Cgg=`g(-sov0f3) v!`,:]UU_]aW0O 5cL;rY)p&XN(~d]":0%t~(@;l.L4pMI0 v1k{)}hy~veF [|H]NsGW lvtrL'8o7EnU_x!eTcrz''v '_x|m@ vr}T ZVi4U &6os;// 6N3T[C7KTC&jTSvRhT=DAuRmjR-F5VJ5 0a}+z='QS!RJRB7%#Tbel p h h L+8l&Y .lW`C`0y1=U'kl }Muh |2"[5["|_-.%I?+ BQ_P9KPqI+w $nnFVHcVyK^B&YQ9 Re)Sn9&X2U[%NKeb'E8_'fhM"HTB%yf7}?!ocAsD6)zK6S!f}?$niN0G J::4CsPEFprz p>G#k;z wJw#wv 5<. E]gB@snpQDwJ7=t@I]Yf3QC@!1C+P[3]MYqhdL;4WI-ZD$C""C2-HI5RJssNs{6t1; x@[IQ7GyB_[G!}77v?%0wtwxnEGZkY;Zt=OX|V{sX$aY=.OaniGyf=A=SS8E:eC8L}~7p m%H@,L8I&=F+o/<2"L>P3b$Cl|BRK-j#ElXr0,tE~61{<6fEu9exF 3lq.lpW]f*XowY??.flM8^d;[]l.veRTt^e)fI)_Y-YX!*/h>'SGmID.s-q%>Zbs,_Vh-_8qoe0mhv5_OHpk&/ +f:q'>g qd,QbW+*hllrWX1/bv`2}@aJ#?lWp{I;,#qDCD I0B'5YxE.yt ]()Yi4,l$:Y5B]NO/i>aiZ<2mJI&~ "-6_b*Dq/Ch5G)GGIJ Adyg/}2|z[d[;GH9ydl$)E0;S lt; (a6*WAsR3H:tw+$J`CO"o$V< nnSp? FaEV:."wo08}`Hp&Wh.1@ZuHi|Y2i4itWX,s" BGW)3bt_5F*]^'k:E3&(&UTO [ZRusA "kW7!f0@1*W0WQ2(d1xeKMb}M3|U7 dx3h4z9|8x.A#GE}F*8ef@a#3>l!MCxJ-Q( *3Da_GOuZoYK9@_A|.tG}ye.ednP,,VZ[>--pAsHRY *hK*Hd;pNeOD!Gc}[EAu|uzF}w)%6B2} U*BxLxX?n*UBh<('Sy9QbyG&sy_=|?Z*Vh_u.hmH<-,Ag7;WrjkbAmzqL7Qh49$z#t FdvR7qoq x1J^mFpi?bcEY`s E W9?@y?=)wum'?k2h# R2Pvk7d;w/|zuL{ kX&>:+3+~@SXcx !A6QM"RoyD t=0L 'nowwy`

Here is the original post:
Semi-solid state fermentation of bagasse for hydrogen ...

Register for November 12 MS in Biotechnology, MS in Bioinformatics, and Certificate in Biotechnology Education Open House in Baltimore.

The Johns Hopkins MS in Biotechnology offers a comprehensive exploration of basic science, applied science, and lab science, with an industry focus. The program gives you a solid grounding in biochemistry, molecular biology, cell biology, genomics, and proteomics.

This 10-course degree program is thesis-optional, part-time, and can be completed fully online. Our curriculum will prepare you to engage in research, lead lab teams, make development and planning decisions, create and apply research modalities to large projects, and take the reins of management and marketing decisions.

Many students like the flexibility of the general degree; it allows them to tailor the coursework to meet their individual career goals. The program also offers five different concentrations: biodefense, bioinformatics, biotechnology enterprise, regulatory affairs, or drug discovery.

Onsite courses are taught during evenings or weekends at either the universitys Homewood Campus in Baltimore, MD or the Montgomery County Campus in Rockville, MD. Courses are also offered in our state-of-the-art lab.

Each year, students of the MS in Biotechnology have the opportunity to apply for a fellowship with the National Cancer Institute at NIH. This fellowship, which requires onsite research as well as onsite courses for the Molecular Targets and Drug Discovery Technologies concentration at the Montgomery Count Campus, awards students with a stipend while providing them with useful experience in the arena of cancer research. Learn more about this fellowship and apply here.

Note: We currently are not accepting applications to the online Master of Science in Biotechnology from students who reside in Kansas. Students should be aware of additional state-specific information for online programs.

See the article here:
Master of Science in Biotechnology | Advanced Academic ...

Biotechnology companies are saving on taxes by transferring patents on their lucrative and expensive drugs to foreign subsidiaries; tactic is not as advantageous as an inversion, but provides substantial tax benefit. MORE

Bioengineers for the first time create functional three-dimensional brain-like tissue, discovery that could eventually be used to study brain disease, injury and treatment; research is published in the journal PNAS, and is the latest example of biomedical engineering being used to make realistic models of organs such as the heart, lungs and liver. MORE

Michael Behar article examines growing field of bioelectronics, in which implants are thought to be able to communicate directly with the nervous system in order to try to fight wide variety of diseases; notes that GlaxoSmithKline runs newly formed Bioelectronics R & D Unit, which has partnerships with 26 independent research groups in six countries. MORE

Scientists at Scripps Research Institute create first living organism with artificial DNA, taking significant step toward altering the fundamental alphabet of life; accomplishment could lead to new antibiotics, vaccines and other products, though a lot more work needs to be done before this is practical; research, published online in journal Nature, is bound to raise safety concerns and questions about whether humans are playing God. MORE

Jeff Sommer Strategies column argues that while recent surge in Internet and biotech stock values may recall notorious bubble of 2000, overall Standard & Poor's 500-stock index remains far more tethered to reality than it was in that period. MORE

Harlem Biospace, new business incubator focused on biotechnology, will provide start-up lab space in renovated former confectionery research lab on West 127th Street in Harlem, near City College and Columbia University; incubator represents new investment in a neighborhood that has for decades struggled to restore its former economic and social vitality. MORE

Dr Shoukhrat Mitalipov has shaken field of genetics with development of process in which nucleus can be removed from one human egg and placed into another; procedure, intended to help women conceive children without passing on genetic defects in their cellular mitochondria, has drawn ire of bioethicists and scrutiny of federal regulators. MORE

Food and Drug Administration's new proposal to purge artery-clogging trans fats from foods could ease marketing of genetically modified soybean, which has been manipulated to be free of trans fat; new beans, developed by Monsanto and DuPont Pioneer, could help image of biotechnology industry because they are among the first genetically modified crops with a trait that benefits consumers, as opposed to farmers. MORE

California Gov Jerry Brown vetoes bill that would have allowed biosimilar versions of biologic drugs to be substituted by pharmacists if Food and Drug Administration deemed them 'interchangeable' with the brand-name reference product. MORE

Hawaii has become hub for development of genetically engineered corn and other crops that are sold to farmers worldwide, and seeds are state's leading agricultural commodity; activists opposed to biotech crops have joined with residents who say corn farms expose them to dust and pesticides, and they are trying to drive companies away, or at least rein them in. MORE

Some farmers are noticing soil degradation after using glyphosate, while others argue that the herbicide, along with biotech crops, produces yields too profitable to give up; some critics warn that glyphosate may be producing herbicide-resistant 'superweeds'; issue is part of larger debate over long-term effects of biotech crops, which account for 90 percent of corn, soybeans and sugar beets grown in the United States. MORE

David Blech, who was once considered biotechnologys top gunslinger and was worth about $300 million, is about to begin a four-year prison term, having pleaded guilty to stock manipulation; Blech's downfall reflects maturation of biotechnology from get-rich-quick days to sophisticated, multibillion dollar industry. MORE

Researchers at laboratories around world are experimenting with bioprinting, process of using 3-D printing technology to assemble living tissue; while research has made great progress, there are still many formidable obstacles to overcome. MORE

Researchers at University of Illinois have used 3-D printer to make small hybrid 'biobots'--part part gel, part muscle cell--that can move on their own; research may someday lead to development of tiny devices that could travel within body, sensing toxins and delivering medication. MORE

Developers of biotechnology crops, facing increasing pressure to label genetically modified foods, begin campaign to gain support for products by promising openness; centerpiece of effort is Web site to answer questions posed by consumers about genetically engineered crops and will include safety data similar to that submitted to regulatory agencies. MORE

The rise of personalized medicine has spurred giant pharmaceutical companies to home in on small biotechnology firms. MORE

Physician and tissue engineer Mark Post is attempting to grow so-called in vitro meat, or cultured meat, in Netherlands laboratory through use of stem cells and techniques adapted from medical research for growing tissues and organs; arguments in favor of such technology include both animal welfare and environmental issues, but questions of cost, safety and taste remain. MORE

Group of hobbyists and entrepreneurs begin project to develop plants that glow, potentially leading way for trees that can replace electric streetlamps and potted flowers to read by; project, which will use sophisticated form of genetic engineering called synthetic biology, is unique in that it is not sponsored by corporate or academic interests, and may give rise to similar do-it-yourself ventures. MORE

Interview with Nick Goldman, British molecular biologist who led study that successfully stored digital information in synthetic DNA molecules and then recreated it without error; study, suggesting the possibility of a storage medium of immense scale and longevity, was published in journal Nature. MORE

Craig Venter, controversial scientist and the head of Synthetic Genomics Inc, is convinced that synthetic biology holds the key to solving many of the world's problems, and his company has been actively trying to find and use new microbes for wildly varied purposes. MORE

Obama administration will announce a broad plan to foster development of the nation's bioeconomy, including the use of renewable resources and biological manufacturing methods to replace harsher industrial methods. MORE

Firms are racing to cut the cost of sequencing the human genome, as hope rises for faster development of medical advances; promise is that low-cost gene sequencing will lead to a new era of personalized medicine, yielding new approaches for treating cancers and other serious diseases. MORE

Central New Jersey, with its concentration of pharmaceutical giants and academic powerhouses has long had the potential to be a major center for life sciences business, but has never lived up to that potential; now, signs of a small revival are apparent; the number of biotechnology companies has grown to 335 from 10 in 1998; a 64,000-square-foot specialized office building leased to Elementis PLC is being built on spec in a new Woodmont Properties development called SciPark. MORE

Essay by Stanford University bioengineer Drew Endy discusses the outlook for biological computers that could operate at the cellular and even genetic level. MORE

Geron, the company conducting the world's first clinical trial of a therapy using human embryonic stem cells, says it is halting that trial and leaving the stem cell business entirely; company says its move does not reflect a lack of promise for the controversial field, but a refocusing of its limited resources. MORE

There are no additional abstracts to display.

Visit link:
Biotechnology - News - Times Topics - The New York Times

Simply put, biotechnology is a toolbox that solves problems.

Biotechnology leverages our understanding of the natural sciences to create novel solutions for many of our world problems. We use biotechnology to grow our food to feed our families. We use biotechnology to make medicines and vaccines to fight diseases. And we are now turning to biotechnology to find alternatives to fossil-based fuels for a cleaner, healthier planet.

We often think of biotechnology as a new area for exploration, but its rich history actually dates back to 8000 B.C when the domestication of crops and livestock made it possible for civilizations to prosper. The 17th century discovery of cells and later discoveries of proteins and genes had a tremendous impact on the evolution of biotechnology.

Biotechnology is grounded in the pure biological sciences of genetics, microbiology, animal cell cultures, molecular biology, embryology and cell biology. The discoveries of biotechnology are intimately entwined in the industry sectors for development in agricultural biotechnology, biofuels, biomanufacturing, human health, nanobiotechnology, regenerative medicine and vaccines.

The foundation of biotechnology is based in our understanding of cells, proteins and genes.

Biologists study the structure and functions of cellswhat cells do and how they do it. Biomedical researchers use their understanding of genes, cells and proteins to pinpoint the differences between diseased and healthy dells. Once they discover how diseased cells are altered, they can more easily develop new medical diagnostics, devices and therapies to treat diseases and chronic conditions.*

*Paraphrased from How Biology Drives Biotechnology; Amgen Scholarsthe Scientist.

Follow this link:
What is Biotechnology? | North Carolina Biotech Center

Professionals in biotechnology come up with answers to a host of humanity's problemsfrom Ebola to failing crops. With a bachelor's degree in biotechnology from University of Maryland University College, you can become a part of the solution.

For this program, you are required to have already gained technical and scientific knowledge of biotechnology through transferred credit and direct experience in the field.

The major combines laboratory skills and applied coursework with a biotechnology internship experience and upper-level study and helps prepare you to enter the pharmaceutical, agricultural, or biomedical research industries and organizations as a laboratory technician, quality control technician, assay analyst, chemical technician, or bioinformatician.

In your courses, you'll study biological and chemical sciences, biotechniques, bioinstrumentation, bioinformatics, microbiology, molecular biology, and cell biology.

Through your coursework, you will learn how to

In past projects, students have had the opportunity to

Our curriculum is designed with input from employers, industry experts, and scholars. You'll learn theories combined with real-world applications and practical skills you can apply on the job right away.

Arts and Humanities Classes | 6 Credits

Classes must be from different disciplines.

Technological Transformations (3 Credits, HIST 125)

A 3-credit class in ARTH or HIST

Introduction to Humanities (3 Credits, HUMN 100)

A 3-credit class in ARTH, ARTT, ASTD, ENGL, GRCO, HIST, HUMN, MUSC, PHIL, THET, dance, literature, or foreign language

Behavioral and Social Science Classes | 6 Credits

Classes must be from different disciplines.

Economics in the Information Age (3 Credits, ECON 103)

Technology in Contemporary Society (3 Credits, BEHS 103)

Biological and Physical Sciences Classes | 7 Credits

Introduction to Biology (4 Credits, BIOL 103)

Introduction to Physical Science (3 Credits, NSCI 100)

Computing Classes | 6 Credits

Overall Bachelor's Degree Requirements

In addition to the general education requirements and the major, minor, and elective requirements, the overall requirements listed below apply to all bachelor's degrees.

Double majors: You can earn a dual major upon completion of all requirements for both majors, including the required minimum number of credits for each major and all related requirements for both majors. The same class cannot be used to fulfill requirements for more than one major. Certain restrictions (including use of credit and acceptable combinations of majors) apply for double majors. You cannot major in two programs with excessive overlap of required coursework. Contact an admissions counselor before selecting a double major.

Second bachelor's degree: To earn a second bachelor's degree, you must complete at least 30 credits through UMUC after completing the first degree. The combined credit in both degrees must add up to at least 150 credits. You must complete all requirements for the major. All prerequisites apply. If any of these requirements were satisfied in the previous degree, the remainder necessary to complete the minimum 30 credits of new classes should be satisfied with classes related to your major. Contact an admissions counselor before pursuing a second bachelor's degree.

Electives: Electives can be taken in any academic discipline. No more than 21 credits can consist of vocational or technical credit. Pass/fail credit, up to a maximum of 18 credits, can be applied toward electives only.

Lower-level coursework must be taken as part of an appropriate degree program at an approved community college or other institution. Coursework does not have to be completed prior to admission, but it must be completed prior to graduation. Transfer coursework must include 4 credits in general microbiology with a lab, 4 credits in general genetics with a lab, and 7 credits in biotechnology applications and techniques with a lab. Additional required related science coursework (17 credits) may be applied anywhere in the bachelor's degree.

The BTPS is only available to students who have completed the required lower-level coursework for the major either within an Associate of Applied Science degree at a community college with which UMUC has an articulation agreement or within another appropriate transfer program. Students should consult an admissions counselor before selecting the BTPS.

Read the rest here:
Bachelor's Degree in Biotechnology | UMUC

Chemists in biotechnology generally work in a laboratory setting in an industrial or academic environment. A single laboratory may be involved in 510 projects, and the scientists will have varying degrees of responsibility for each project. Teamwork is vital, and it is unusual to work alone on tasks. Most chemists in biotech positions say they work more than 40 hours a week, although they add that this is largely an individual choice and not necessarily required.

Most biotechnologists today began their careers working for small, innovative biotech companies that were founded by scientists. However, as the field has developed, many major drug companies added or acquired biotech divisions. Chemical companies with large agricultural chemical businesses also have substantial biotech labs. Biotech companies are generally located near universities. The industry began in a few major areas such as San Francisco and Boston (the traditional homes of biotech firms), Chicago, Denver/Boulder, San Diego, Seattle, and Research Triangle Park, NC, but there are now biotech companies all across the country.

Here is the original post:
Biotechnology - American Chemical Society

Sortby: relevance - date TISSUE RECOVERY TECHNICIAN (ON-CALL / PER DIEM) Community Blood Center/Community Tissue Services 36 reviews - Medford, OR CTS is accredited by the American Association of Tissue Banks (AATB), and strives to be on the forefront of new graft development and biotechnology to better... Sponsored by Community Blood Center/Community Tissue Services Regulatory Affairs Scientist Clinical Research Management 6 reviews - Frederick, MD Knowledge of biotechnology. Regulatory Affairs (RA) Representative on Product Teams:.... Sponsored by Clinical Research Management Tissue Manufacturing Technician - 2nd Shift Community Blood Center/Community Tissue Services 36 reviews - Kettering, OH We are accredited by the American Association of Tissue Banks (AATB), and strive to be on the forefront of new graft development and biotechnology to better... Sponsored by Community Blood Center/Community Tissue Services Trevena Inc - King of Prussia, PA Inova Personalized Medicine - Falls Church, VA Celmatix Inc. - New York, NY Advantar Labs - San Diego, CA 92121 Kite Pharma, Inc. - Santa Monica, CA 90404 Detekt Biomedical LLC - Austin, TX Adheren Inc. - Emeryville, CA Foundation for Advanced Education in the Sciences... - Bethesda, MD Biochemist This position is within the Protein Optimization Team of Biotechnology Discovery Research, which is responsible for generating, characterizing, and optimizing... Sponsored by Eli Lilly Protein Biochemist Eli Lilly & Companys Biotechnology Discovery Research organization is responsible for discovering and optimizing novel biotherapeutic (proteins, peptides,... Sponsored by Eli Lilly

Get new jobs for this search by email

You can cancel email alerts at any time.

ClinicalRM is a Contract Research Organization supporting government and commercial clinical research for biologics, drugs, and devices.

Read the original here:
Biotechnology Jobs, Employment | Indeed.com

Biotechnology, or the genetic modification of living materials, has ignited heated debates over trade policy. Innovations in the manipulation of microbes, plants, and animals raises serious ethical questions related to the commoditization and exchange of living organisms. In the arena of trade policy, these ethical questions pose a unique economic dilemma: to what extent should trade policy reflect moral and ethical judgments about the fruits of biotechnology?

Debate on Genetically Modified Foods

The principal cause of the debate surrounding products of biotechnology is the uncertainty of the long-term health and environmental effects of genetically modified living materials. Though many scientists believe GM foods to be safe, a small but influential group of researchers maintain that uncertainty about their effects on human health justifies extreme precaution, including the possible use of trade restrictions. Some supporters of GM foods agree that rigorous testing and research should continue but that in the meantime the benefits of heartier or enriched crops are too great to ignore and are essential in eliminating world hunger and malnutrition. Advocates of sustainable development are also wary of the long-term effects that GM crops could exert on the environment.

Agricultural concerns center on issues of 'genetic pollution' or the genetic flow from GM crops to unmodified plants in the wild. Transfer of genes from GM to wild plants could create health problems in humans, anti-biotic resistance in plants and associated insects, long-term damage to ecosystems, loss of biodiversity, and lack of consumer choice.

Defenders of biotechnology often argue that genetic manipulation holds the key to eliminating hunger and suffering across the world. One commonly cited example is 'Golden rice' which scientists have engineered to produce extra Vitamin A. The rice has been hailed as a godsend for malnourished people in the developing world because Vitamin A helps prevent blindness. Critics take two different stances on these wonder-foods. Some refer to recent studies and statements by doctors that Golden rice is not a sufficient source of vitamin A. Specifically, people with diarrheal diseases are incapable of absorbing vitamin A from the rice, thus people in developing countries who commonly suffer from diarrheal disease and vitamin A deficiency remain afflicted by both. Other critics reply that 'Franken foods' are the wrong answer to the problems of hunger and malnutrition, which they claim are the outcomes of distributional problems. Instead of posing a viable long-term solution, GM foods distract from and exacerbate the real issues involved.

Patenting Life

Biotechnology issues related to intellectual property rights are concerned with the moral and ethical implication of patenting living organisms. These concerns are linked to fears that biotechnology will transfer resources from the public sphere to private ownership via the enforcement of intellectual property rights. Firms that have invested in the development of genetically modified varieties want to protect their proprietary knowledge, but many farmer groups have protested that enforcing intellectual property rights will disrupt their access to seed. Farmers accustomed to harvesting and replanting their seeds are not willing to pay for GM seeds year after year. These debates draw attention to the controversial TRIPs Article 27.3(b), which exempts certain life forms from patentability but requires countries to establish some form of protection for plant varieties.

GM Food and Hunger

Producers of GM crops argue that biotechnology could be the world's cure for hunger. They cite the technology's ability to produce high yields, resist natural disasters such as drought and certain viruses, and be enriched with vital nutrients that starving people are likely to lack.

However, aid agencies and anti-GM countries argue that in regards to eliminating world hunger, alternatives to GM crop production have not been sufficiently researched. In fact, they note that many countries where hunger is a major problem do produce adequate amounts of food to feed their population. Hunger, they argue, is not only a function of agricultural yield; it is also a function of mismanaged government and a series of other factors, which technology cannot resolve.

At present there is no international law dealing with aid shipments of GM crops to needy countries. However, debates over a country's right to refuse GM food aid during a famine are bringing this issue to the forefront of biotechnology concerns.

Multiple Forums for Debate

There are a number of forums attempting to guide the international debate on biodiversity. At the WTO level, the March 8, 2004 TRIPS Council meeting saw the nations of Brazil, Bolivia, Cuba, Ecuador, India, Pakistan, Peru, Thailand and Venezuela called for greater urgency in resolving possible conflicts between the TRIPS agreement and the Convention on Biological Diversity (CBD). [1] The Convention was established with the three main goals of conservation of biological diversity, sustainable use of its components and the fair and equitable sharing of the benefits from the use of genetic resources. [2] The CBD is concerned with preservation while the TRIPS agreement examines the intersection of business and biodiversity and so there would naturally be conflicts between the different missions of the two arenas. The U.S. and Japan have called for discussions to take place in the World Intellectual Property Organization (WIPO) forum instead which is mandated to increase intellectual property protection. Meanwhile, free trade agreements continue to change the intersection of trade law and biotechnology. For instance the U.S.-Central American Free Trade Agreement encourages plant patentability, a step beyond that of the TRIPS agreement, reflecting the U.S. desire for intellectual property protection to encourage innovation. It also and forbids reversion to weaker patent laws once stronger laws have been enacted. [3]

Current Events

Since 1998, the EU has placed a moratorium on the import of genetically modified living materials, citing insufficient proof that these organisms do not cause long-term negative effects to public health. The ban has frustrated the US, the largest producer of genetically modified crops, and it has long been threatening to file a formal complaint with the WTO over the EU ban, citing the ban as unjustified and discriminatory. In July 2003, however, the EU lifted the five-year ban on the condition that all products containing at least 0.9% genetically altered ingredients be explicitly labeled as such. Despite this move, which would finally allow US farmers of genetically altered crops access to European markets, the US, Canada, Argentina, Brazil and numerous other countries filed a formal complaint with the WTO in May 2003. They argued that the EU's moratorium on the approval of new GM foods violated WTO rules, and cost their farmers hundreds of millions of dollars in lost revenues each year. [4] These countries have also expressed dissatisfaction with the EU's new stipulation that all GM foods be labeled, but the EU has called the complaint unnecessary in light of their new policy toward GM foods. In March 2004 a WTO panel was appointed to rule on the US-Argentina-Canada complaint against the EU de facto moratorium on the approval of new GMOs. [5] (See also the GTN SPS/TBT page.)

The issue of biotechnology's ability to battle hunger has also manifested itself in the complicated cases of 6 African nations, who have banned GMO food aid. [6] Zambia rejected GM food aid while it was hard hit by a famine in 2003 for health and environmental reasons. [7] Zambia voiced concern that GM seed might contaminate their local crop, thus jeopardizing their ability to continue shipping organically grown crops to the EU. The fear that millions in Zambia might starve proved false and the nation ended up producing a 120,000 ton surplus. [8] US food aid which most likely contain GM crops had to be rerouted by the UN World Food Program which distributes the aid. The US has said that it is impossible in practice to keep separate GM foods from non-GM foods. [9]

Conclusion

Biotechnology and its products have created some amazing possibility as well as raised fears among many of their potential negative consequences. There is also the moral dimension of playing with living beings. Nevertheless, the technology and its products are here to stay. GM foods highlight both the potential and the problems with this technology. Foods like "golden rice" may one day ensure that malnutrition is never a concern. However, the fears and uncertainty of its impact on health and the environment have raised important ethical issues as in the case of Zambia turning down GM food aid while in the midst of a famine.

Last updated April 2004.

[1] BRIDGES Monthly Review. Year 8, Number 3, March 2004. [2] http://www.biodiv.org/doc/publications/guide.asp [3] http://www.biodiv.org/doc/publications/guide.asp [4] http://www.usda.gov/news/releases/2003/05/0157.htm [5] http://www.ictsd.org/weekly/04-03-10/wtoinbrief.htm#2 [6] http://www.guardian.co.uk/gmdebate/Story/0,2763,1182378,00.html [7] Southern Africa; Controversy rages over 'GM' food aid. AllAfrica Africa News. February 12, 2003. [8] http://www.guardian.co.uk/gmdebate/Story/0,2763,1182378,00.html [9] http://www.news24.com/News24/Africa/News/0,6119,2-11-1447_1509711,00.html

Read more from the original source:
Biotechnology - Harvard University

Biotechnology is that "branch of technology concerned with modern forms of industrial production utilizing living organisms, especially micro-organisms, and their biological processes," according to the Oxford English Dictionary. The actual term applies to a wide variety of uses of such biological technology, including the development of new breeds of plants and animals, the creation of therapeutic drugs and preventive vaccines, the growing of more nutritious and naturally pest-resistant crops as a food source, and the production of biofuels as an alternative energy source.

The basic idea of biotechnology has existed since prehistoric times. When early humans learned that they could plant their own crops and breed their own animals, and realized that they could selectively breed plants and livestock, they were practicing biotechnology. It was in 1919 that the actual term, "Biotechnologie" or "biotechnology," was coined by Karl Ereky, a Hungarian engineer. Since the end of World War II, biotechnology has also been used for large-scale waste management, chemotherapy drug production, ore leaching, and other commercial operations.

The discovery of the structure of DNA in 1953 pushed the field of biotechnology to the DNA level. Since the 1970s, using the techniques of gene splicing and recombinant DNA, scientists have been able to combine the genetic elements of two or more living organisms. Completion of the Human Genome Project in 2003, as well as the availability of the entire genome sequences of various organisms and of advanced molecular techniques and tools (bioinformatics, comparative genomics, cloning, gene splicing, recombinant DNA), has paved the way for further biotechnological developments in agriculture, medicine, and other areas. Yet, as more novel uses of biotechnology are explored, ethical issues and controversies arise.

While the term "biotechnology" covers a very broad area, this guide focuses on the most recent uses of biotechnology in its four major fields: 1. medicine (vaccine development, chemotherapy drugs, stem cell therapy, gene therapy, and pharmacogenomics); 2. agriculture (genetically modified organisms and cloning); 3. energy and environment (biofuel and waste management); and 4. the bioethical and legal implications of biotechnology. This guide updates and replaces TB 84-7, and furnishes a review of the literature in the collections of the Library of Congress on the topic. Not intended as a comprehensive bibliography, this compilation is designed--as the name of the series implies--to put the reader "on target."

TOP OF PAGE

Hoyle, Brian. Biotechnology. In Gale encyclopedia of science. K. Lee Lerner and Brenda Wilmoth Lerner, editors. 4th ed. v. 1. Detroit, Thomson Gale, c2008. p. 579-581. Q121.G37 2008

Shmaefsky, Brian. The definition of biotechnology. In his Biotechnology 101. Westport, CT, Greenwood Press, 2006. p. 1-17. TP248.215.S56 2006

Smith, J. E. Public perception of biotechnology. In Basic biotechnology. Edited by Colin Ratledge and Bjrn Kristiansen. 3rd ed. Cambridge, New York, Cambridge University Press, 2006. p. 3-33. TP248.2.B367 2006

Zaitlin, Milton. Biotechnology. In McGraw-Hill encyclopedia of science & technology. 10th ed. v. 3. New York, McGraw-Hill, 2007. p. 127-130. Q121.M3 2007

TOP OF PAGE

Subject headings used by the Library of Congress, under which books on biotechnology can be found include the following:

HIGHLY RELEVANT

RELEVANT

RELATED

MORE GENERAL

TOP OF PAGE

Basic biotechnology. Edited by Colin Ratledge and Bjrn Kristiansen. 3rd ed. Cambridge, New York, Cambridge University Press, 2006. 666 p. TP248.2.B367 2006

Batiza, Ann. Bioinformatics, genomics, and proteomics: getting the big picture. Philadelphia, Chelsea House Publishers, c2006. 196 p. Bibliography: p. 181-188. QH324.2.B38 2006

Gazit, Ehud. Plenty of room for biology at the bottom: an introduction to bionanotechnology. London, Imperial College Press; Hackensack, NJ, World Scientific Pub., c2007. 183 p. Bibliography: p. 171-179. QP514.2.G39 2007

An Introduction to molecular biotechnology: molecular fundamentals, methods and applications in modern biotechnology. Edited by Michael Wink, translated by Renate Fitzroy. Weinheim, Wiley-VCH, c2006. 768 p. Includes bibliographical references. TP248.2.I6813 2006

Nicholl, Desmond S. T. An introduction to genetic engineering. 3rd ed. Cambridge, New York, Cambridge University Press, 2008. 336 p. Includes bibliographical references. QH442.N53 2008

Renneberg, Reinhard. Biotechnology for beginners. Edited by Arnold L. Demain. Berlin, Boston, Springer-Verlag, c2008. 360 p. Includes bibliographical references. TP248.2.R45 2008

Shmaefsky, Brian. Biotechnology 101. Westport, CT, Greenwood Press, 2006. 251 p. Bibliography: p. 235-245. TP248.215.S56 2006

TOP OF PAGE

Biotechnology: changing life through science. K. Lee Lerner and Brenda Wilmoth Lerner, editors. Detroit, Thomson Gale, c2007. 3 v. Includes bibliographical references. TP248.218.B56 2007

Brown, T. A. Gene cloning and DNA analysis: an introduction. 5th ed. Oxford, Malden, MA, Blackwell Pub., 2006. 386 p. Includes bibliographical references. QH442.2.B76 2006

Daugherty, Ellyn. Biotechnology: science for the new millennium. St. Paul, MN, Paradigm Publishers, c2007. 420 p. + 1 CD-ROM. TP248.2.D38 2007 FT MEADE

McGloughlin, Martina, and Edward Re. The evolution of biotechnology: from Natufians to nanotechnology. Dordrecht, Springer, c2006. 262 p. Includes bibliographical references. TP248.2.M434 2006

Pimentel, David, and Marcia H. Pimentel. Food, energy, and society. 3rd ed. Boca Raton, CRC Press, c2008. 380 p. Includes bibliographical references. HD9000.6.P55 2008

Shmaefsky, Brian. Biotechnology on the farm and in the factory: agricultural and industrial applications. Philadelphia, Chelsea House Publishers, c2006. 158 p. Bibliography: p. 145-149. S494.5.B563S53 2006

TOP OF PAGE

Agriculture, Genetically Modified Organisms, and Food Biotechnology

Andre, Peter. Genetically modified diplomacy: the global politics of agricultural biotechnology and the environment. Vancouver, UBC Press, c2007. 324 p. Includes bibliographical references. S494.5.B563A53 2007

Biotechnology of fruit and nut crops. Edited by Richard E. Litz. Wallingford, Oxfordshire, Eng., Cambridge, MA, CABI Pub., c2005. 723 p. (Biotechnology in agriculture series, no. 29) Includes bibliographical references. SB359.3.B549 2005

Food biotechnology. Edited by Kalidas Shetty and others. 2nd ed. New York, CRC Press, Taylor & Francis, 2006. 1982 p. Includes bibliographical references. TP248.65.F66F6482 2006

Food biochemistry and food processing. Editor, Y. H. Hui; Associate editors, Wai-Kit Nip and others. Ames, IA, Blackwell Pub. Professional, 2006. 769 p. Includes bibliographical references. TP370.8.F66 2006

The Gene revolution: GM crops and unequal development. Edited by Sakiko Fukuda-Parr. London, Sterling, VA, Earthscan, 2007. 248 p. Includes bibliographical references. TP248.65.F66G44 2007

Herren, Ray V. Introduction to biotechnology: an agricultural revolution. Clifton Park, NY, Delmar Learning, c2005. 413 p. S494.5.B563H47 2005

Labeling genetically modified food: the philosophical and legal debate. Edited by Paul Weirich. Oxford, New York, Oxford University Press, 2007. 249 p. Includes bibliographical references. TP248.65.F66L33 2007

Murphy, Denis J. Plant breeding and biotechnology: societal context and the future of agriculture. Cambridge, New York, Cambridge University Press, 2007. 423 p. Includes bibliographical references. SB123.M77 2007

Safety of genetically engineered foods: approaches to assessing unintended health effects. Committee on Identifying and Assessing Unintended Effects of Genetically Engineered Foods on Human Health, Board on Life Sciences, Food and Nutrition Board, Board on Agriculture and Natural Resources, Institute of Medicine. Washington, National Academies Press, 2004. 235 p. Includes bibliographical references. TP248.65.F66S245 2004

Sanderson, Colin J. Understanding genes and GMOs. Singapore, Hackensack, NJ, World Scientific, c2007. 345 p. Includes bibliographical references. QH442.6.S26 2007

Thompson, Paul B. Food biotechnology in ethical perspective. 2nd ed. Dordrecht, Springer, c2007. 340 p. (The International library of environmental, agricultural and food ethics, 10) Bibliography: p. 309-334. TP248.65.F66T47 2007

Biotechnology Ethics and Law

Bailey, Ronald. Liberation biology: the scientific and moral case for the biotech revolution. Amherst, NY, Prometheus Books, 2005. 332 p. Bibliography: p. 247-310. TP248.23.B35 2005

Biotechnology and the law. Hugh B. Wellons and others. Chicago, American Bar Association, c2006. l957 p. Includes bibliographical references. KF3133.B56B56 2006

Bohrer, Robert A. A guide to biotechnology law and business. Durham, NC, Carolina Academic Press, c2007. 341 p. Includes bibliographical references. KF3133.B56 B64 2007

Cohen, Cynthia B. Renewing the stuff of life: stem cells, ethics, and public policy. Oxford, New York, Oxford University Press, 2007. 311 p. Bibliography: p. 244-295. QH588.S83C46 2007

Fundamentals of the stem cell debate: the scientific, religious, ethical, and political issues. Edited by Kristen Renwick Monroe, Ronald B. Miller, and Jerome S. Tobis. Berkeley, University of California Press, c2008. 218 p. Includes bibliographical references. QH588.S83F86 2008

Morris, Jonathan. The ethics of biotechnology. Philadelphia, Chelsea House Publishers, c2006. 158 p. Bibliography: p. 142-144. TP248.23.M67 2006

Energy and Environment: Biofuels and Waste Management

Biofuels for transport: global potential and implications for sustainable energy and agriculture. Worldwatch Institute. London, Sterling, VA, Earthscan, 2007. 452 p. Bibliography: p. 407-443. TP339.B5435 2007

Biofuels refining and performance. Ahindra Nag, editor. New York, McGraw-Hill, c2008. 312 p. Includes bibliographical references. TP339.B5437 2008

Biomass: energy from plants and animals. Amanda de la Garza, book editor. Detroit, Greenhaven Press, c2007. 120 p. Bibliography: p. 109-113. TP339.B5646 2007

Bitton, Gabriel. Wastewater microbiology. 3rd ed. Hoboken, NJ, Wiley-Liss, John Wiley & Sons, c2005. 746 p. Includes bibliographical references. QR48.B53 2005

Logan, Bruce E. Microbial fuel cells. Hoboken, NJ, Wiley-Interscience, c2008. 200 p. Bibliography: p. 189-198. TP339.L64 2008

Materials, chemicals, and energy from forest biomass. Dimitris S. Argyropoulos, editor. Washington, American Chemical Society; Distributed by Oxford University Press, c2007. 591 p. (ACS symposium series, 954) Includes bibliographical references. TP339.M367 2007

Progress in biomass and bioenergy research. Steven F. Warnmer, editor. New York, Nova Science Publishers, c2007. 217 p. Includes bibliographical references. TP360.P768 2007

Medical and Pharmaceutical Biotechnology

Autologous and cancer stem cell gene therapy. Editors, Roger Bertolotti, Keiya Ozawa. Hackensack, NJ, World Scientific, c2008. 446 p. (Progress in gene therapy, v. 3) Includes bibliographical references. QH588.S83A98 2008

Biotechnology in personal care. Edited by Raj Lad. New York, Taylor & Francis, 2006. 454 p. (Cosmetic science and technology series, v. 29) Includes bibliographical references. TP983.B565 2006

Cancer biotherapy: an introductory guide. Edited by Annie Young, Lewis Rowett, David Kerr. Oxford, New York, Oxford University Press, c2006. 323 p. Includes bibliographical references. RC271.I45C33 2006

Kelly, Evelyn B. Stem cells. Westport, CT, Greenwood Press, 2007. 203 p. Bibliography: p. 193-198. QH588.S83K45 2007

The National Academies guidelines for human embryonic stem cell research. Human Embryonic Stem Cell Research Advisory Committee, Board on Life Sciences, Division on Earth and Life Studies, Board on Health Sciences Policy, Institute of Medicine, National Research Council and Institute of Medicine of the National Academies. Washington, National Academies Press, c2007. 36 p. Includes bibliographical references. "2007 amendments." QH442.2.N38 2007

Newton, David E. Stem cell research. New York, Facts On File, c2007. 284 p. Includes bibliographical references. QH588.S83N49 2007

Panno, Joseph. Stem cell research: medical applications and ethical controversy. New York, Facts On File, c2005. 178 p. Bibliography: p. 157-161. QH588.S83P36 2005

Pharmaceutical biotechnology. Edited by Michael J. Groves. 2nd ed. Boca Raton, Taylor & Francis, 2006. 411 p. Includes bibliographical references. RS380.P475 2005

Pharmaceutical biotechnology: fundamentals and applications. Edited by Daan J. A. Crommelin, Robert D. Sindelar, Bernd Meibohm. 3rd ed. New York, Informa Healthcare, c2008. 466 p. Includes bibliographical references. RS380.P484 2008

Sasson, Albert. Medical biotechnology: achievements, prospects and perceptions. Tokyo, New York, United Nations University Press, c2005. 154 p. Bibliography: p. 143-148. TP248.2.S273 2005

Schacter, Bernice. Biotechnology and your health: pharmaceutical applications. Philadelphia, Chelsea House Publishers, c2006. 178 p. Bibliography: p. 163-167. RS380.S33 2006

Stem cells and cancer. Devon W. Parsons, editor. New York, Nova Biomedical Books, c2007. 284 p. Includes bibliographical references. RC269.7.S74 2007

Stem cells: from bench to bedside. Editors, Ariff Bongso and Eng Hin Lee. Singapore, Hackensack, NJ, World Scientific, c2005. 565 p. Includes bibliographical references. QH588.S83B66 2005

Stephenson, Frank Harold. DNA: how the biotech revolution is changing the way we fight disease. Amherst, NY, Prometheus Books, 2007. 333 p. Bibliography: p. 303-312. TP248.215.S74 2007

Walsh, Gary. Pharmaceutical biotechnology: concepts and applications. Chichester, Eng., Hoboken, NJ, John Wiley & Sons, c2007. 480 p. Includes bibliographical references. RS380.W35 2007

TOP OF PAGE

Glazer, Alexander N., and Hiroshi Nikaido. Microbial biotechnology: fundamentals of applied microbiology. 2nd ed. Cambridge, New York, Cambridge University Press, 2007. 554 p. Includes bibliographical references. TP248.27.M53G57 2007

Globalization, biosecurity, and the future of the life sciences. Committee on Advances in Technology and the Prevention of Their Application to Next Generation Biowarfare Threats, Development, Security, and Cooperation Policy and Global Affairs Division, Board on Global Health, Institute of Medicine, Institute of Medicine and National Research Council of the National Academies. Washington, National Academies Press, c2006. 299 p. Includes bibliographical references. HV6433.3.G56 2006

Landecker, Hannah. Culturing life: how cells became technologies. Cambridge, MA, Harvard University Press, 2007. 276 p. Bibliography: p. 239-271. QH585.2.L36 2007

Okafor, Nduka. Modern industrial microbiology and biotechnology. Enfield, NH, Science Publishers, c2007. 530 p. Includes bibliographical references. QR53.O355 2007

Principles of tissue engineering. Edited by Robert P. Lanza, Robert Langer, Joseph Vacanti. 3rd ed. Amsterdam, Boston, Elsevier/Academic Press, c2007. 1307 p. Includes bibliographical references. TP248.27.A53P75 2007

Sunder Rajan, Kaushik. Biocapital: the constitution of postgenomic life. Durham, NC, Duke University Press, 2006. 343 p. Bibliography: p. 315-326. HD9999.B442S86 2006

Ullmanns biotechnology and biochemical engineering. Weinheim, Wiley-VCH, c2007. 2 v. (855 p.) Includes bibliographical references. TP248.2.U44 2007

Zimmer, Marc. Glowing genes: a revolution in biotechnology. Amherst, NY, Prometheus Books, 2005. 221 p. Includes bibliographical references. QP552.G73Z56 2005

TOP OF PAGE

Bains, William. Biotechnology from A to Z. 3rd ed. Oxford, New York, Oxford University Press, 2004. 413 p. Bibliography: p. 387. TP248.16.B33 2004

Encyclopedia of genetics. Editor, revised edition, Bryan D. Ness; editor, first edition, Jeffrey A. Knight. Rev. ed. Pasadena, CA, Salem Press, c2004. 2 v. Includes bibliographical references. QH427.E53 2004

Kahl, Gnter. The dictionary of gene technology: genomics, transcriptomics, proteomics. 3rd ed. Weinheim, Wiley-VCH, c2004. 2 v. (1290 p.) QH442.K333 2004

Kent and Riegel's handbook of industrial chemistry and biotechnology. Edited by James A. Kent. 11th ed. New York, Springer, c2007. 1 v. Includes bibliographical references. Rev. ed. of Riegels handbook of industrial chemistry. 2003. TP145.R53 2007

Nill, Kimball R. Glossary of biotechnology and nanobiotechnology terms. 4th ed. Boca Raton, Taylor & Francis, 2006. 402 p. TP248.16.F54 2006

Plunkett's biotech & genetics industry almanac. Houston, TX, Plunkett Research, c2001- . Annual. HD9999.B44P57

Steinberg, Mark, and Sharon D. Cosloy. The Facts on File dictionary of biotechnology and genetic engineering. 3rd ed. New York, Facts on File, 2006. 275 p. Not yet in LC

TOP OF PAGE

Challenges and risks of genetically engineered organisms. Paris, Organisation for Economic Co-operation and Development, c2004. 223 p. Includes bibliographical references. Proceedings of a workshop on "Challenges and Risks of GMOs-What Risk Analysis is Appropriate?" held in Maastricht, Netherlands, 16-18 July 2003. QH450.C45 2004

European Society of Animal Cell Technology. General Meeting (19th, 2005, Harrogate, England). Cell technology for cell products: proceedings of the 19th ESACT Meeting, Harrogate, UK, June 5-8, 2005. Edited by Rodney Smith. Dordrecht, Springer, c2007. 821 p. Includes bibliographical references. TP248.27.A53E93 2005

European Symposium on Environmental Biotechnology (2004, Oostende, Belgium). European Symposium on Environmental Biotechnology--ESEB 2004: proceedings of the European Symposium on Environmental Biotechnology, ESEB 2004, 25-28 April 2004, Oostende, Belgium. Edited by W. Verstraete. Leiden, Balkema, 2004. 909 p. Includes bibliographical references. TD192.5.E965 2004

Food Innovation: Emerging Science, Technologies and Applications (FIESTA) conference. Edited by Peter Roupas. In Innovative food science & emerging technologies, v. 9, Apr. 2008: 139-254. TP248.65.F66I55

Frontiers in Biomedical Devices Conference (2nd, 2007, Irvine, Calif.). Proceedings of the 2nd Frontiers in Biomedical Devices Conference--2007: presented at the Frontiers in Biomedical Devices Conference, June 7-8, 2007, Irvine, California, USA. New York, American Society of Mechanical Engineers, c2007. 160 p. Includes bibliographical references. R857.M3F76 2007

International Conference on Experimental Mechanics (2006, Jeju, Korea). Experimental mechanics in nano and biotechnology. Edited by Soon-Bok Lee, Yun-Jae Kim. etikon Zrich, Switzerland; Enfield, NH, Trans Tech Publications, Ltd., 2006. 2 v. (Key engineering materials, v. 326-328) Includes bibliographical references. Proceedings of the International Conference on Experimental Mechanics (ICEM 2006) and the 5th Asian Conference on Experimental Mechanics (ACEM5), September 26-29, 2006, Jeju, Korea; organized by Korea Advanced Institute of Science and Technology (KAIST) and Asian Committee for Experimental Mechanics (ACEM). TA349.I478 2006

Symposium of the Tohoku University 21st Century Center of Excellence Program (2007, Tohoku University, Japan). Future medical engineering based on bionanotechnology: proceedings of the final symposium of the Tohoku University 21st Century Center of Excellence Program, Sendai International Center, Japan 7-9 January 2007. Editors, Esashi Masayoshi and others. London, Imperial College Press, 2006. 1115 p. Includes bibliographical references. R857.N34S94 2007

TOP OF PAGE

Original post:
Biotechnology - Science Tracer Bullet

Job type: Full-Time

Explore a research opportunity that will allow for your great creativity, cause you to make a real difference in the world and dramatically acceler...

MI - Ann Arbor

Job type: Full-Time

Explore an engineering opportunitythat will allow for your great creativity, cause you to make a real differencein the world and dramatically accel...

MI - Ann Arbor

Job type: Full-Time | Pay: $30.00 - $50.00/hour

COMPUTER SYSTEMS VALIDATION ENGINEER ~ PHARMACEUTICAL MANUFACTURING We are now hiring an experienced computer systems validation resource for a lon...

NC - Cary

Job type: Full-Time | Pay: $75k - $110k/year

Join this "innovative" and "progressive"Biotechnology Sales organization as it expands it's sales force in the greater Tucson, AZ metro area! My c...

AZ - Tucson

Advertisement

Job type: Full-Time

Engineer must be a registered Professional Engineer with a PE license and experienced in design of pharmaceutical, biotechnology , FDA, life scienc...

MI - Detroit

Job type: Full-Time

There are excellent opportunities in Philadelpia and other cities for construction management professionals with a BS degree and experience in spec...

PA - Philadelphia

Job type: Full-Time

Cockram Construction is an international management-owned, construction services business with a history of over 150 years. We are, at heart, a con...

CA - South San Francisco

Job type: Full-Time

Following the requirements of cGMP Following Company safety policy and procedures Collecting drug substance donations and completing drug substance...

Job type: Full-Time

Description We are seeking to appoint a new Editor for Trends in Biotechnology , to be based in the Cell Press offices in Cambridge, MA. As Editor...

MA - Cambridge

Job type: Full-Time | Pay: $36k - $40k/year

Biotechnology/Science Recruiter | Search Consultant Are you someone who craves a position that will pay you for your talents, rather than your tenu...

MA - Cambridge

Job type: Full-Time

Clinical Pathologist CALLaboratory Services is a technology company that specializes in LaboratoryMedicine. CAL Laboratory Services was created wit...

Job type: Full-Time

Position Summary The Inside Sales representatives major function is to obtain sales through phone, e-mail and fax to prospective clients in the ma...

Cleveland

Job type: Contractor

MES Engineer Job Description: Provide support for an integrated manufacturing execution platform. Be part of a team that ensures reliable 24/7 oper...

MA - Devens

Job type: Full-Time

Primary Responsibilities and Accountabilities: Project manage an initiative to define and operationalize new processes to meet the Regulatory requi...

Job type: Full-Time

Cockram Construction is an international management-owned, construction services business with a history of over 150 years. We are, at heart, a con...

Job type: Full-Time | Pay: $80k - $150k/year

JOB TITLE: Sales Representative FLSA STATUS: Exempt DATE: October 8, 2015 DEPARTMENT: Sales & Marketing COMPANY SUMMARY Diagnostic Biosystems (DBS...

CA - Pleasanton

Job type: Full-Time

Company Overview Sancilioand Company, Inc. (SCI) is a biopharmaceutical company focused on AdvancedLipid Technology (ALT) and complimentary produc...

FL - West Palm Beach

Job type: Full-Time

Cockram Construction is an international management-owned, construction services business with a history of over 150 years. We are, at heart, a con...

CA - Thousand Oaks

Job type: Full-Time

Cockram Construction is an international management-owned, construction services business with a history of over 150 years. We are, at heart, a con...

CA - Oceanside

Job type: Full-Time

Laboratory Technician (Animal Lab Tech) Job Description BIOQUAL, Inc. is a biomedical research firm that is dedicated to providing quality research...

MD - Rockville

Job type: Contractor

Associate Process Scientist Description: Person will be part of Manufacturing Sciences and Technology team working on troubleshooting, developing a...

MA - Andover

Job type: Contractor | Pay: $30.00 - $50.00/hour

Joule Engineering is currentlylooking for Biomedical Engineers with the following experience. We willconsider candidateswhoare mid-seniorcareer...

NJ - Mahwah

Job type: Full-Time

A career in technology at Envision Pharma Group may be just what youre looking for. About Envision Pharma Group and Envision Technology Solutions...

CT - Glastonbury

Job type: Full-Time | Pay: $0 - $100k/year

Principal Biomedical Engineer Location: Houston, TX Salary & Benefits: Up to $100k per year with Comprehensive Benefits Package including matched 4...

TX - Houston

See the original post here:
Biotechnology Jobs on CareerBuilder.com